LeMaitre Vascular (NASDAQ:LMAT) Updates Q4 2024 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) issued an update on its fourth quarter 2024 earnings guidance on Thursday morning. The company provided EPS guidance of 0.470-0.510 for the period, compared to the consensus EPS estimate of 0.460. The company issued revenue guidance of $54.9 million-$56.9 million, compared to the consensus revenue estimate of $55.6 million. LeMaitre Vascular also updated its FY 2024 guidance to 1.910-1.960 EPS.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on LMAT shares. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Tuesday, August 27th. Barrington Research reiterated an “outperform” rating and set a $92.00 target price on shares of LeMaitre Vascular in a report on Friday, September 20th. Cantor Fitzgerald started coverage on LeMaitre Vascular in a research note on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 target price for the company. JMP Securities upped their price target on LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 20th. Finally, Lake Street Capital started coverage on LeMaitre Vascular in a report on Friday, August 2nd. They issued a “buy” rating and a $105.00 price objective for the company. Three investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $94.67.

LeMaitre Vascular Stock Performance

Shares of LeMaitre Vascular stock traded down $0.66 during midday trading on Thursday, hitting $88.39. The company had a trading volume of 191,960 shares, compared to its average volume of 122,304. The company has a 50 day moving average of $89.48 and a 200 day moving average of $82.73. The stock has a market capitalization of $1.99 billion, a P/E ratio of 52.93, a P/E/G ratio of 2.29 and a beta of 0.88. LeMaitre Vascular has a 52-week low of $45.96 and a 52-week high of $93.32.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.05. The firm had revenue of $55.85 million during the quarter, compared to the consensus estimate of $54.98 million. LeMaitre Vascular had a return on equity of 12.41% and a net margin of 18.33%. The company’s revenue was up 11.4% on a year-over-year basis. During the same period last year, the company earned $0.37 earnings per share. Equities research analysts forecast that LeMaitre Vascular will post 1.86 EPS for the current year.

Insider Activity at LeMaitre Vascular

In related news, Director David B. Roberts sold 3,063 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total transaction of $251,380.41. Following the completion of the sale, the director now owns 14,114 shares of the company’s stock, valued at $1,158,335.98. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 10.79% of the stock is currently owned by insiders.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.